Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 12/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 12/20 | 0.54 |
| ▸ | MC4R | P32245 | 1/20 | 0.54 |
| ▸ | APLNR | P35414 | 2/20 | 0.53 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.51 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1029686 | 0.95 | MC4R (0.51) | OPRM1OPRK1MC4RAPLNRCXCR4 | |
| SCHEMBL4301705 | 0.91 | MC4R (0.52) | OPRM1OPRK1MC4RAPLNRCXCR4 | |
| SCHEMBL197800 | 0.90 | APLNR (0.49) | OPRM1OPRK1MC4RAPLNRC5AR1 | |
| SCHEMBL4807604 | 0.89 | APLNR (0.56) | OPRM1OPRK1MC4RAPLNRCXCR4 | |
| SCHEMBL4807584 | 0.89 | APLNR (0.56) | OPRM1OPRK1MC4RAPLNRCXCR4 | |
| SCHEMBL1029282 | 0.88 | OPRM1 (0.52) | OPRM1OPRK1MC4RAPLNRCXCR4 | |
| SCHEMBL1030624 | 0.88 | OPRM1 (0.55) | OPRM1OPRK1MC4RAPLNRCXCR4 | |
| SCHEMBL1028505 | 0.87 | OPRM1 (0.56) | OPRM1OPRK1MC4RAPLNRCXCR4 | |
| SCHEMBL4804770 | 0.87 | APLNR (0.55) | OPRM1OPRK1APLNRCXCR4 | |
| SCHEMBL4804787 | 0.87 | APLNR (0.55) | OPRM1OPRK1APLNRCXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286739-A1 | PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286739-A1 | PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | NPR3, RXFP3, RXFP1 | OPRM1 242/4885OPRK1 572/4885MC4R 999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.